DANGEROUS DIMERS: Linking mutant KRAS proteins with normal partners can make lung cancer (dark splotches) resistant to anticancer drugs. © iSTOCK.COM/OG PHOTO
THE PAPER C. Ambrogio et al., “KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS,” Cell, 172:857-68.e15, 2018. BAD ACTOR Genes in the RAS family regulate cell growth and differentiation, and mutations can render them oncogenic. One such proto-oncogene, KRAS, frequently turns up in human cancers, including lung cancer, and is associated with resistance to chemotherapies including MEK inhibitors. PAIRING UP Some proteins encoded by RAS genes appear to function as dimers—linked pairs of identical molecules. Pasi Jänne, a medical oncologist at Dana-Farber Cancer Institute, used a fluorescence resonance energy transfer (FRET) assay to find that the KRAS protein does, too. They then fashioned a mutant KRAS that was dimerization-deficient. PARTNERS IN CRIME Jänne and colleagues compared tumor development in mice with ...
